<DOC>
	<DOCNO>NCT01109030</DOCNO>
	<brief_summary>The purpose study determine whether Pioglitazone adjunct Citalopram effective treatment moderate severe depression</brief_summary>
	<brief_title>Pioglitazone Adjunct Moderate Severe Depressive Disorder</brief_title>
	<detailed_description>Pioglitazone Ppar-gamma agonist anti diabetic drug . It also show , certain anti inflammatory neuro-protective effect . In recent year propose Ppar-gamma agonist may effect mood cognition . In animal study one human case report well pilot study human subject drug improve symptom depression . A randomized control double blind design provide evidence efficacy drug major depressive disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Chlordiazepoxide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosis Major depressive disorder base DSMIV TR criterion Age 1850 Hamilton Depression Rating scale &gt; =22 Signing inform consent form Citalopram drug choice patient irrespective eligibility criterion Problems Axes Pregnancy lactation Serious life threaten disease take antidepressant recent month Electroconvulsive shock recent two month , take psychotropic agent Diabetes control drug insulin ( patient lifestyle intervention include ) , Liver disease , Congestive heart failure Class III IV Metabolic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>double blind</keyword>
	<keyword>placebo control</keyword>
</DOC>